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Abstract
Background:  Wee1 is a tyrosine kinase regulating S-G2 cell cycle transition through the
inactivating phosphorylation of CDC2. The inhibition of Wee1 kinase by a selective small molecule
inhibitor significantly enhances the anti-tumor efficacy of DNA damaging agents, specifically in p53
negative tumors by abrogating S-G2 checkpoints, while normal cells with wild-type p53 are not
severely damaged due to the intact function of the G1 checkpoint mediated by p53. Since the
measurement of mRNA expression requires a very small amount of biopsy tissue and is highly
quantitative, the development of a pharmacodynamic (PD) biomarker leveraging mRNA expression
is eagerly anticipated in order to estimate target engagement of anti-cancer agents.
Results: In order to find the Wee1 inhibition signature, mRNA expression profiling was first
performed in both p53 positive and negative cancer cell lines treated with gemcitabine and a Wee1
inhibitor, MK-1775. We next carried out mRNA expression profiling of skin samples derived from
xenograft models treated with the Wee1 inhibitor to identify a Wee1 inhibitor-regulatory gene set.
Then, the genes that were commonly modulated in both cancer cell lines and rat skin samples were
extracted as a Wee1 inhibition signature that could potentially be used as a PD biomarker
independent of p53 status. The expression of the Wee1 inhibition signature was found to be
regulated in a dose-dependent manner by the Wee1 inhibitor, and was significantly correlated with
the inhibition level of a direct substrate, phosphorylated-CDC2. Individual genes in this Wee1
inhibition signature are known to regulate S-G2 cell cycle progression or checkpoints, which is
consistent with the mode-of-action of the Wee1 inhibitor.
Conclusion: We report here the identification of an mRNA gene signature that was specifically
changed by gemcitabine and Wee1 inhibitor combination treatment by molecular profiling. Given
the common regulation of expression in both xenograft tumors and animal skin samples, the data
suggest that the Wee1 inhibition gene signature might be utilized as a quantitative PD biomarker in
both tumors and surrogate tissues, such as skin and hair follicles, in human clinical trials.
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Background
A diversity of anti-tumor agents is known to cause DNA
damage resulting in the activation of G1 and G2 cell cycle
checkpoints [1-3]. Normal somatic cells with functional
p53 arrest the cell cycle both at G1 and G2 phases by
transactivating p53 regulatory genes upon DNA damage
[4,5]. However, the G1 checkpoint is frequently compro-
mised in multiple types of cancers due to loss-of-function
mutations in the p53 gene [6,7]. Cancer cells with dys-
functional p53 are more reliant on the G2 checkpoint in
order to repair damaged DNA. Wee1 kinase, which acts as
a critical driver of G2-M cell cycle progression, is involved
in S-G2 checkpoints through inactivating phosphoryla-
tion of CDC2 at the Y15 residue [8,9]. When DNA is dam-
aged in cells, Wee1 is phosphorylated at S549 by several
kinases, including CHEK1, followed by binding to 14-3-3
proteins which leads to stabilization of the Wee1 protein
[10-12]. The phosphorylated and stabilized Wee1
increases the level of inactivated phoshorylated-CDC2,
preventing the damaged cells from entering into prema-
ture mitosis without repairing the DNA. Although the
activation mechanism is still controversial, various studies
have established the essential function of Wee1 in the reg-
ulation of S-G2 cell cycle arrest in response to DNA dam-
age.
Given the pivotal role of Wee1 in the S-G2 checkpoint, the
inhibition of Wee1 kinase is expected to exert an anti-
tumor effect by abrogating the G2 checkpoint, specifically
in p53 negative tumors in combination with DNA damag-
ing drugs. Several previous studies have illustrated the
p53-context dependent anti-tumor efficacy of Wee1 inhi-
bition  in vitro [13-15]. A potent Wee1 inhibitor,
PD0166283, sensitizes p53-negative cancer cells to radia-
tion-induced cell death compared with p53-positive cells
[13,14]. It was also shown that Wee1 silencing by siRNA
potentiates the anti-tumor effect of Adriamycin in p53-
defective HeLa cells, although normal mammary epithe-
lial cells with wild-type p53 are not severely damaged
[15]. Recently, we have developed a new class of small
molecule Wee1 inhibitor as a G2 checkpoint abrogator,
MK-1775 [16]. The Wee1 inhibitor induces cell death
selectively in p53-negative cells compared with isogenic
p53-positive cells in combination with DNA damaging
agents such as gemcitabine, carboplatin, and cisplatin.
The assessment of the primary substrate, phospho-CDC2,
ensured that the p53 context-specificity was mediated by
Wee1 inhibition. We also demonstrated that significant
sensitization to various DNA damaging agents is observed
in p53 negative xenograft tumors in rodents, providing
the initial evidence that Wee1 inhibition enhances the
effect of standard care medicine in vivo via abrogating the
G2 checkpoint. Clinical development of the Wee1 inhibi-
tor as a p53 context-specific sensitizer would potentially
improve the low therapeutic indices and narrow therapeu-
tic window from which current chemotherapeutic agents
are suffering.
Development of pharmacodynamic (PD) biomarkers is
critically important in cancer drug development in order
to examine whether drugs are modulating the intended
therapeutic targets or pathways [17-19]. Conventionally,
immunohistochemistry (IHC) assays for protein-biomar-
kers have played an important role in assessing the target
engagement level of drugs; such biomarkers include phos-
phorylated-EGFR for Iressa [20], and phosphorylated-
CRKL for Gleevec [21]. For the Wee1 inhibitor, the phos-
phorylation level of CDC2 is a promising PD biomarker
since it is a primary substrate for Wee1 kinase [14-16].
Indeed, reduction of phosphorylated-CDC2 at Tyr15 has
been observed in both in vitro and in vivo studies, confirm-
ing that Wee1 inhibitors were engaging the target. Further-
more, the level of phosphorylation at Y15 is correlated
with the anti-tumor efficacy of the Wee1 inhibitor. How-
ever, IHC assays for protein biomarkers have presented
several challenges when developed in a clinical setting.
First, IHC markers require a relatively large amount of
biopsy tissue and morphological integrity, and these
requirements are difficult to fulfill for some tumor biopsy
methods, such as fine needle aspiration [22]. Second, IHC
assays for proteins are not quantitative, since the expres-
sion level is usually indicated by the intensity scores of
chromogens ranging from 0 to 3, which is a relatively arbi-
trary index. The development of mRNA gene expression
signatures for anticancer drugs is an intriguing approach
to overcome these drawbacks, since the measurement of
mRNA requires smaller amounts of biopsy samples, and
is highly quantitative when measured with an RT-qPCR
assay. Multiple previous studies have measured mRNA
expressions as PD gene biomarkers for estimating target
engagement or predicting early response of anti-cancer
agents such as KDR [23], COXII [24], or histone deacety-
lase inhibitors [25], providing evidence that mRNA gene
signatures are suitable to quantitatively represent the indi-
ces.
The purpose of the present study was to develop a Wee1
inhibition gene signature measuring the change in expres-
sion caused by a combination treatment of Wee1 inhibi-
tor and gemcitabine. Genome-wide gene expression in
both cancer cells and skin tissues was analyzed to find a
Wee1 gene signature that can be utilized in both tumor
and surrogate tissues. The availability of the Wee1 gene
signature in skin samples offers an advantage due to the
difficulty of obtaining tumor biopsies from patients. In
addition, dose-dependent expression changes of the Wee1
gene signature in rodent xenograft tumors and skin sam-
ples were correlated with the level of phosphorylated-
CDC2 and anti-tumor efficacy of the Wee1 inhibitor. The
expression pattern and function of the Wee1 gene signa-Molecular Cancer 2009, 8:34 http://www.molecular-cancer.com/content/8/1/34
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ture are consistent with mode of action of the Wee1 inhib-
itor as a G2 checkpoint abrogator. These data ensure that
the Wee1 gene signature identified in the present study
can be utilized to assess the target engagement level of
Wee1 inhibitor in both preclinical and clinical studies.
Results
Identification of Wee1 inhibition signature in cell lines
We previously reported on a novel class of Wee1 inhibi-
tor, MK-1775, (2-alkyl-6-anilino-1-aryl-1, 2-dihydro-3H-
pyrazole [3, 4-d]pyrimidin-3-one) with an IC50 value of
5.2 nM against recombinant human Wee1 in in vitro
kinase assays. MK-1775 potentiates the anti-cancer effi-
cacy of DNA damaging agents such as gemcitabine, cispl-
atin, and carboplatin both in vitro and in vivo [16]. In
order to find an mRNA gene signature that indicates target
engagement of Wee1 inhibitor as a PD biomarker, we ana-
lyzed genome-wide expression profiles of p53-positive
and -negative isogenic paired cell lines (TOV21G-Vec and
TOV21G-shp53) treated with gemcitabine and Wee1
inhibitor. TOV21G is an ovarian cancer cell line with
wild-type p53 gene. The isogenic pairs of p53-positive and
-negative TOV21G cells were generated by transfection
with a vector expressing an shRNA targeting p53 or an
empty vector, respectively [26]. We employed p53 paired
cell lines to find PD markers available in cancer cells inde-
pendent of p53 status. First, gemcitabine was used to treat
the p53 matched pair cell lines for 24 hr to activate S-G2
checkpoints. Next, increasing concentrations of MK-1775
were administered to the cells for 8 hr following the gem-
citabine treatment. We confirmed that more significant
apoptosis was induced in p53-negative cells compared
with p53-positive counterparts in accordance with the
previous study [16] (Figure 1). While 28% and 44% of the
sub-G1 fraction was induced in p53 negative cells treated
with 100 nM and 300 nM of the Wee1 inhibitor respec-
tively, 5.9% and 6.4% of the sub-G1 fraction was observed
in p53-positve cells. In parallel with the efficacy study,
mRNA recovered at 8 and 16 hr after the Wee1 inhibitor
treatment was subjected to microarray analysis to find the
PD gene biomarker. We extracted genes whose expression
levels in Wee1 inhibitor-treated cell lines were signifi-
cantly up- or down-regulated compared to those of gem-
citabine treated cell lines. We pared down the signature by
extracting the genes whose expression exhibited greater
than three-fold change in both p53 positive and negative
cell lines in at least one treatment condition. A hierarchi-
cal clustering of the gene signature composed of 55 genes
is shown in Figure 2, and the genes exhibited similar
expressional regulation in both p53 positive and negative
cells. Moreover, most of the genes showed time-depend-
ent and concentration-dependent expression changes that
are suitable features of PD biomarkers. Functional assess-
ment of the gene signature by a hypergeometric test for
gene enrichment indicated that S-G2/M cell cycle genes
were significantly enriched in down-regulated genes
(DNA replication: p = 8.4 × 10-9; S phase of mitotic cell
cycle: p = 5.3 × 10-8; mitotic cell cycle: p = 1.69 × 10-5) and
up-regulated genes (nucleosome assembly in M phase: p
= 1.3 × 10-23). This finding is consistent with the function
of Wee1 kinase that prevents premature mitosis entry.
Identification of Wee1 inhibition signature in rat skin 
samples
Although measuring PD biomarkers in tumors is prefera-
ble, skin is an attractive tissue since it is easily accessible
for analyzing PD effects, especially for tumor types for
which biopsies are difficult. In attempting to identify PD
biomarkers in surrogate skin tissues in vivo, expression
profiles were analyzed between rat skin samples treated
with gemcitabine only and a gemcitabine/Wee1 inhibitor
combination. Subcutaneous xenograft tumors were
formed by injection of the human colorectal cancer,
WiDr, in the hind flank of immunodeficient nude rats. On
the 8th day, gemcitabine was intraveneously (IV) admin-
istrated to the animals. Twenty-four hours later, an
TOV21G p53 positive and negative matched pair cell lines  treated with gemcitabine and Wee1 inhibitor Figure 1
TOV21G p53 positive and negative matched pair cell 
lines treated with gemcitabine and Wee1 inhibitor. 
TOV21G positive- and negative cell lines were treated with 
30 nM gemcitabine, and 100 and 300 nM of the Wee1 inhibi-
tor. At 8 hr post Wee1 inhibitor treatment, cells were sub-
jected to flow cytometry analysis. The percentage of the 
subG1 fraction corresponds to apoptotic cells. TOV21G-
Vec: wild-type p53 cells; TOV21G-shp53: p53-deficient cells; 
Gem: gemcitabine. **, P < 0.01, compared with TOV21G-
Vec.
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increasing concentration of the Wee1 inhibitor was
infused via IV infusion for 8 hr. Then, total RNAs from
each rat skin tissue were purified and applied to microar-
ray analysis to extract a gene signature whose expression
significantly changed in response to gemcitabine and the
Wee1 inhibitor treatment. The selection criteria to deter-
mine up- and down-regulated genes are described in the
Materials and Methods in detail. Briefly, error-weighted
ANOVA was applied between the Wee1 inhibitor-treated
samples and gemcitabine treated samples, and the genes
whose expression changed more than 1.5-fold in either
1.0 or 3.0 mg/kg/hr treatment were further selected down.
As a result, 48 genes out of 39,558 probes were found to
be significantly changed by gemcitabine/Wee1 inhibitor
combination treatment compared with gemcitabine treat-
ment only. Hierarchical clustering of the gene signature in
rat skin is displayed in Figure 3 as a heatmap, showing the
dose-dependent changes in their expressions.
Extraction of Wee1 inhibition gene signature available in 
both tumor and skin tissues
To find genes that can be used as a PD biomarker in both
tumor and skin tissues, a common gene signature that was
changed in both cancer cell lines and skin tissue was
extracted. In both experiments, claspin (CLSPN), mini-
chromosome maintenance complex component 10
(MCM10), and F-box protein 5 (FBXO5) were signifi-
cantly changed, indicating that they could be promising
expression PD biomarkers for the Wee1 inhibitor inde-
pendent of p53 status and the tissue type. CCNE1 was
included in the gene set changed in skin samples, whereas
CCNE2 was found in the analysis of p53 paired cell lines
in vitro. Given the well-conserved function between
CCNE1 and CCNE2, both genes were selected for the
Wee1 inhibition gene signature for further validation. Pre-
viously reported functions of the five genes in the Wee1
inhibition gene signature which relate to the S-G2 cell
cycle are shown in Table 1, inferring a relationship
between Wee1 inhibitor-mediated gene expression
changes and S-G2 cell cycle checkpoints.
Identification of a gene signature changed by gemcitabine and Wee1 inhibitor combination in both p53 positive and negative  paired cell lines Figure 2
Identification of a gene signature changed by gemcitabine and Wee1 inhibitor combination in both p53 posi-
tive and negative paired cell lines. TOV21G positive and negative cell lines were treated with gemcitabine and Wee1 
inhibitor as described in the legend of Figure 1, and mRNA from each treatment sample was applied to microarray analysis. A 
gene signature whose expression significantly changed in response to gemcitabine and Wee1 inhibitor treatment was 
extracted. Each row represents a sample from each treatment group. Each column represents a gene. Red, up-regulated genes; 
green, down-regulated genes.
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Identification of a gene signature changed by gemcitabine and Wee1 inhibitor in rat skin sample Figure 3
Identification of a gene signature changed by gemcitabine and Wee1 inhibitor in rat skin sample. (A) Expression 
profile of rat skin samples treated with gemcitabine and Wee1 inhibitor. Nude rats were administered with gemcitabine and 
increasing concentrations of the Wee1 inhibitor via IV infusion. At 8 hr post Wee1 inhibitor administration, mRNA from each 
rat skin sample was applied to microarray analysis. A gene signature whose expression significantly changed in response to 
gemcitabine and Wee1 inhibitor treatment was extracted. Each row represents a sample from each treatment group. Each col-
umn represents a gene. Red, up-regulated genes; green, down-regulated genes. (B) Wee1 gene signature commonly changed in 
both cancer cell lines and skin samples. The common signature for both tumor and surrogate tissues was identified by extract-
ing commonly regulated genes in global expression profiling. Gem: gemcitabine; Wee1i: Wee1 inhibitor (MK-1775).
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Table 1: Function of Wee1 inhibition gene signature
Gene Function
CLSPN Clspn triggers a checkpoint arrest of cell cycle by activating CHEK1 in response to DNA damage
FBXO5 Fbxo5 is a mitotic regulator interacting with CDC20 and inhibits the anaphase promoting complex
MCM10 Involved in S phase progression which interacts with chromatin during S phase and dissociates G2
CCNE1 CyclinE1 forms a complex with and functions as a regulatory subunit of CDK2
CCNE2 CyclinE2 forms a complex with and functions as a regulatory subunit of CDK2Molecular Cancer 2009, 8:34 http://www.molecular-cancer.com/content/8/1/34
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Although the 5 genes were selected as a common signa-
ture in both cancer and surrogate skin tissues, most of the
cancer gene signature and rat skin signature showed statis-
tically significant expression changes in reciprocal experi-
ments, suggesting conserved Wee1-mediated expression
changes in both tumor and the surrogate tissues.
Validation of the Wee1 inhibition gene signature
Expression changes of the Wee1 inhibition gene signature
in cancer cells have thus far been assessed only in cultured
cell lines. To validate the Wee1 inhibition gene signature,
we analyzed mRNA expression of the five genes in WiDr
xenograft tumors in vivo. With the same dosing regimen
used in the rat skin microarray, nude rats bearing WiDr
xenograft tumors were administered with gemcitabine
and the Wee1 inhibitor combination. To analyze the gene
markers, total RNA samples from the WiDr xenograft
tumors were purified 8 hr after Wee1 inhibitor adminis-
tration, and the expression of the Wee1 gene signature was
measured by quantitative RT-PCR. As a result, the expres-
sion of all five genes was up-regulated by gemcitabine
treatment, and subsequently down-regulated by the Wee1
inhibitor treatment, which was a similar expression pat-
tern to that of TOV21G p53 matched pair cells in vitro
(Figure 4). For example, gemcitabine treatment increased
the expression of CLSPN by 2-fold, and Wee1 inhibitor
down-regulated the expression to one-fourth compared
with the gemcitabine single treatment sample. We also
measured the level of phosphorylated CDC2 (Y15) in the
WiDr xenograft tumor samples by Western blotting. The
expression pattern of the Wee1 gene signature was similar
to that of phosphorylated-CDC2 (Y15) when the correla-
tion coefficient (R) was calculated between phosphor-
ylated-CDC2 and mRNA expression of each gene in the
Wee1 gene signature (Figure 4). This correlation supports
the idea that functions of each gene in the Wee1 inhibi-
tion signature relate to the S-G2 cell cycle and/or its check-
points. Regarding anti-tumor efficacy, statistically
significant enhancement of efficacy for gemcitabine was
observed, when co-treated with more than 0.5 mg/kg/hr
(8 hr IV infusion) of MK-1775 (data not shown).
Finally, to confirm that the selected genes constitute a gen-
uine Wee1 inhibition signature independent of the inhi-
bition modality, the mRNA expression of the five genes
were examined in WiDr cells treated with siRNA for Wee1
in vitro. Twenty-four hours after gemcitabine treatment,
siRNA for Wee1 was transferred to the cells and the expres-
sion of the candidate signature was analyzed. In accord-
ance with the results obtained in the Wee1 inhibitor
study, significant down-regulation of mRNA expression
was observed when Wee1 was silenced with siRNA (Figure
5).
Discussion
A number of reports have shown the usefulness of protein
biomarkers to assess target engagement of anti-cancer
agents in tumors [20,21,27]. Some protein markers for the
Wee1 inhibitor have also been reported in preclinical
studies, including phosphorylated-CDC2 and -histone H3
[14-16]. Assays for protein-markers are in general not
quantitative and require large amounts of biopsy speci-
mens in clinical trials. The same holds true for protein
markers for the Wee1 inhibitor. The development of a
Wee1 gene signature as an mRNA-based expression
biomarker offers some advantages over protein markers.
The Wee1 gene signature presents quantitative data when
measured by RT-PCR. This allows investigators to pre-
cisely correlate the changes in the expression of the Wee1
gene signature and anti-tumor efficacy of the Wee1 inhib-
itor. The Wee1 gene signature is also superior to conven-
tional IHC markers such as phosphorylated-CDC2 in
terms of the required amount of samples. To measure
phosphorylated-CDC2 in cancer, several slices of forma-
lin fixed paraffin embedded tissues (FFPET) are required
for total CDC2, phosphorylated CDC2, and their confir-
mation assays. In contrast, one slice will be sufficient for
multiple repeated measurements of the Wee1 gene expres-
sion signature. Since the quantification and amplification
technologies of mRNA have been advancing rapidly
[28,29], further reduction of required samples might be
possible for analyzing the Wee1 gene signature.
In order to assess accurate target engagement of the Wee1
inhibitor, it is preferable to measure PD biomarkers in
tumors. However, the feasibility of tumor biopsy is
dependent on the tumor type [30,31]. While it is relatively
easy to obtain tumor biopsies for skin cancers, biopsies of
pancreatic or lung cancers are quite difficult. Therefore,
the development of biomarkers that are commonly avail-
able in both tumors and surrogate tissues is of great bene-
fit. Previous studies have proven that skin biopsies can be
used to assess PD biomarkers of anticancer agents as an
easily accessible tissue [32,33]. Although the develop-
ment of mRNA gene expression biomarkers that can be
measured in either tumors or surrogate tissues has been
reported, the present study is unique in that the identified
Wee1 gene signature can be commonly measured in both
tumors and surrogate skin tissues. This was achieved by
applying genome-wide gene expression profiling in the
two tissues and extracting a commonly regulated gene sig-
nature. The Wee1 gene signature in surrogate skin tissues
may accelerate the clinical development of the inhibitor
by enabling biopsies for most patients at multiple time
points.
The Wee1 gene signature is composed of five genes listed
in Table 1. Although the method to identify the signature
was a non-biased genome-wide approach, the function ofMolecular Cancer 2009, 8:34 http://www.molecular-cancer.com/content/8/1/34
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each gene in the signature is closely associated with the
mechanism underlying the Wee1 inhibitor-mediated S-
G2 phase checkpoint abrogation. First, CLSPN is a cell
cycle regulated protein whose expression peaks at S-G2
phases [34]. CLSPN interacts with CHEK1 kinase that also
plays a pivotal role in the S-G2 cell cycle checkpoint, and
association of the two proteins is required for CHEK1 acti-
vation in response to DNA damage [35]. Therefore, down-
regulation of CLSPN expression by the Wee1 inhibitor
would provide additional beneficial effects on S-G2
checkpoint abrogation by preventing the activation of
CHEK1 kinase. Second, MCM10 is a DNA binding protein
involved in the initiation of DNA replication as well as the
elongation step [36]. Interestingly, it was reported that the
depletion of MCM10 by small interfering RNA in cancer
cells accumulates DNA damage and arrests the cells in late
S-G2 phase, suggesting a role for MCM10 in cell cycle
checkpoints [37]. We envision that DNA damage by gem-
citabine arrested the cells in the S-G2 phase, which acti-
vates the DNA repair system in which MCM10 is involved.
The abrogation of the S-G2 phase checkpoint by the Wee1
inhibitor might have reduced the expression of MCM10
without completion of DNA repair. Third, FBXO5, also
known as Emi1, is a cellular inhibitor of the APC/C com-
plex which degradates mitotic cyclins (Cyclin A and B)
[38]. The up-regulation of FBXO5 ensures that the cells are
arrested at S phase by gemcitabine, since FBXO5 inhibits
APC/C during S phases. At the onset of mitosis, it is
known that FBXO5 activity is significantly reduced [39],
which could also explain the down-regulation of FBXO5
Expression changes of Wee1 inhibition signature in xenograft WiDr tumors and their correlation to classical PD marker,  pCDC2 Figure 4
Expression changes of Wee1 inhibition signature in xenograft WiDr tumors and their correlation to classical 
PD marker, pCDC2. Human WiDr colorectal cancer cells were injected subcutaneously into nude rats. After allowing 
tumors to establish for 8 days, gencitabine and Wee1 inhibitor were administered in the nude rats as described in the legend of 
Figure 3. At 8 hr post Wee1 inhibitor administration, mRNA from each WiDr xenograft tumor was applied to quantitative RT-
PCR analysis. To correlate the phosphorylated-CDC2 and Wee1 gene expression signature, the level of the pCDC2 normal-
ized to total CDC2 is shown. The correlation coefficient (R) of pCDC2 expression and each mRNA expression is shown in 
each graph. Data represent mean ± SD. **, P < 0.01, compared with gemcitabine treated sample.
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expression by Wee1 inhibitor. Finally, CyclinE1 and 2 are
well-known regulators of S phase cell cycle progression
[40]. Since the expressional regulation of CyclinE has
extensively been investigated [41], the expression pattern
found in this study was very reasonable. Similar to the
hypothetical mechanism discussed for FBXO5, the expres-
sion pattern of CyclinE1/2 supports the mode-of-action of
the Wee1 inhibitor that causes the disruption of S-G2
checkpoints leading to premature mitotic entry. Although
we have speculated a functional relation between the
Wee1 inhibitor and the gene signature, it would be inter-
esting to further decipher the molecular role of the five
genes in the Wee1 inhibitor-mediated anti-cancer effect.
There are several challenges ahead before using the pre-
clinically developed Wee1 inhibition gene signature in
clinical trials. First, although the present data shows that
the signature can be assessed as a PD biomarker in surro-
gate rat skin tissues, the signature should be evaluated in
human surrogate tissues. Since the Wee1 gene signature is
composed of cell cycle related genes, their expression
changes should be observed in proliferating cells, which is
also supported by the fact that actively proliferating tumor
samples both in vitro and in vivo showed a larger effect size
compared with rat skin tissues. As the actively growing
cells in skin samples would be those from hair follicles or
hair bulbs, a potential surrogate skin tissue utilized in
human clinical trials is scalp punch biopsy, in which hair
density is relatively higher compared with other parts of
the skin [42]. Plucked hair, including hair follicles and
hair bulbs, could be an alternative candidate RNA source
for the Wee1 gene signature (Figure 6). It has been
reported that plucked hairs can be leveraged as a source of
PD markers for other cell cycle inhibitors [43]. Second,
the variability of the Wee1 gene signature is unknown,
which makes it difficult to judge whether the observed
expression changes in the Wee1 gene signature are derived
from the treatment effect, intrapatient variability, or natu-
ral decay of signal. One strategy to address these issues is
to conduct phase 0 trials which are first-in-human studies
performed before standard phase I trials are conducted
[44]. The phase 0 studies may be designed to determine a
statistically significant Wee1 inhibitor-mediated effect on
the expression changes of the Wee1 gene signature. With
the data from multiple time points both pre- and post-
treatment with Wee1 inhibitor, the phase 0 study will pro-
vide us with variability data which will allow researchers
to do a statistical power calculation for the PD effect for a
future standard phase I study.
Despites several challenges for the future of the Wee1 gene
signature, its assessment will have beneficial impacts on
the development of the Wee1 inhibitor. The quantitative
assessment of the signature will allow us to make early
decisions even at dose-setting phase 1 trials by providing
information on whether sufficient target engagement is
achieved or not at tolerable doses.
Conclusion
In this study, we identified a Wee1 gene signature whose
expression was changed in response to a combination
treatment of gemcitabine and Wee1 inhibitor. A common
expressional regulation of the Wee1 gene signature was
observed in xenograft tumor (p53 negative), cultured can-
cer cells (p53 positive and negative), and rat skin tissues
(p53 positive). Although the signature was selected
through genome-wide molecular expression, the func-
tions of the genes are associated with S-G2 cell cycle
checkpoint and their abrogation, which is also supported
by the fact that the phosphorylated CDC2 level that repre-
sents the S-G2 checkpoint activation level is highly corre-
lated with the expression pattern of the Wee1 signature
genes. In addition to the common regulation of the signa-
ture genes independent of the tissue type and p53 status,
Wee1-silencing by siRNA confirmed that the Wee1 gene
signature is generally regulated by gemcitabine and Wee1
inhibition. The present study first found and validated the
gene signature as a PD biomarker for Wee1 inhibitor, and
also presented initial evidence that a common mRNA
siRNA-Wee1 treatment confirms that the selected genes are  the bona-fide Wee1 inhibition gene signature Figure 5
siRNA-Wee1 treatment confirms that the selected 
genes are the bona-fide Wee1 inhibition gene signa-
ture. WiDr colorectal cancer cells were treated with 30 nM 
of gemcitabine and siRNA for Wee1. After 48 hr siRNA 
treatment, mRNA from each was applied to quantitative RT-
PCR analysis for the Wee1 gene signature. Gem: gemcitab-
ine. Data represent mean ± SD. **, P < 0.01, compared with 
gemcitabine treated sample.
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expression-based biomarker in tumors and surrogate tis-
sues can be identified, which is an advantageous feature to
facilitate anticancer drug development.
Methods
Cell culture
WiDr cell lines were obtained from the American Type
Culture Collection, and were cultured according to the
supplier's instructions. TOV21G p53-isogenic matched-
pair cell lines were provided from ROSETTA INPHAR-
MATICS [26], and were cultured with Dulbecco's Modi-
fied Eagle Medium (DMEM, Invitrogen).
Flow cytometric analysis
Cells were first treated with 30 nM gemcitabine
(GEMZER, Lilly) for 24 hr followed by addition of MK-
1775 for 8 hr. Trypsinized single-cells were stained with
propidium iodide with the CycleTEST plus DNA reagent
kit (BD biosciences) and were analyzed in a FACS Calibur
(Becton Dickinson) apparatus.
Expression profiling of TOV21G p53 positive- and 
negative-matched pair cell lines
TOV-21G p53-isogenic matched-pair cell lines were
treated with 30 nM gemcitabine for 24-hr, followed by
addition of MK-1775. At 8-hr or 16-hr after MK-1775
treatment, cells were recovered for RNA extraction.
Hybridization for microarray experiments was performed
as follows: TOV21G-Vec, no treatment control (control)
vs. TOV21G-Vec. No treatment (n = 2); Control vs. TOV-
21G-Vec treated with 30 nM gemcitabine for 24 hr (n = 2);
Control vs. TOV21G-Vec treated with 30 nM gemcitabine
for 24 hr, followed by treatment with 100 nM, 300 nM, or
1000 nM of MK-1775 for 8 hr (n = 2 for each concentra-
tion of MK-1775); Control vs. TOV21G-Vec treated with
30 nM gemcitabine for 24 hr, followed by treatment with
100 nM, 300 nM or 1000 nM of MK-1775 for 16 hr (n =
2 for each concentration of MK-1775). The same hybridi-
zations performed for TOV21G-Vec were also carried out
for the TOV21G-shp53 cell line.
Gene marker findings of in vivo WiDr xenograft nude rats
The PD gene biomarker was investigated in vivo in a WiDr
nude rat xenograft model. Gemcitabine was dosed as an
intravenous bolus (50 mg/kg). After 24 hr of gemcitabine
administration, MK-1775 was dosed via intravenous infu-
sion at doses of 0.5, 1.0, and 3.0 mg/kg/hr for 8 hr. Skin
samples were isolated 8 hr after MK-1775 dosing. Hybrid-
ization for microarray experiments was performed as fol-
lows: Vehicle control pool (control) vs. Vehicle control
self-reference (n = 3); Control vs. gemcitabine 50 mg/kg
(n = 3); Control vs. gemcitabine 50 mg/kg with 0.5, 1.0,
Schematic diagram for finding the Wee1 gene signature available for both tumor and surrogate tissues, and its potential applica- tion to clinical research Figure 6
Schematic diagram for finding the Wee1 gene signature available for both tumor and surrogate tissues, and its 
potential application to clinical research. The present study isolated a gene set that commonly showed expression 
changes in both TOV21G p53 positive and negative matched pair cell lines and rat skin tissues, which led to the identification of 
the Wee1 gene signature available as a PD biomarker for Wee1 inhibitor independent of the p53 status of the tissues analyzed. 
In future clinical trials, the Wee1 gene expression signature can be analyzed from both plucked hair samples and FFPE tumor 
samples to assess the target engagement of the Wee1 inhibitor.
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or 3.0 mg/kg/hr of MK-1775 for 8 hr (n = 3 for each con-
centration of MK-11775).
Total RNA from cultured cells or skin samples was isolated
by using the RNeasy mini kit (Qiagen, #74104) with
DNase I (Qiagen, #79254). Total RNA from skin or tumor
tissues in rat xenograft model was isolated by Trizol rea-
gent (Invitrogen, #15596-018), and the isolated RNA was
repurified with an RNeasy mini kit. The purified RNA
from each sample was converted to cDNA and hybridized
to appropriate reference standards; rat skin microarray:
three vehicle control samples; human cell line microarray:
pooled TOV21G with control vector samples. Next,
microarray analysis was performed with a Rosetta/Merck
microarray, Human 44 k 1.1 and Rat 44 k 1.1. Expression
profiles were analyzed by the microarray software,
Resolver (Rosetta Inpharmatics) to identify the classifier
genes for responder.
Microarray data analysis
1) Rat skin sample: First, error-weighted ANOVA was
applied between 1.0/3.0 mg/kg/hr MK-1775 treated sam-
ples and gemcitabine only treated samples, and the genes
whose expression was significantly changed in both 1.0
and 3.0 mpk treatment (p ≤ 0.001) were extracted. Next,
we selected genes whose expression changed more than
1.5-fold in either 1.0 or 3.0 mg/kg/hr treatment compared
with gemcitabine only treated samples. Then, error-
weighted ANOVA was applied between 3.0 mg/kg/hr MK-
1775 treated samples and 0.5 mpk MK-1775 treated sam-
ples, and the genes whose expression significantly (p ≤
0.05) changed were selected.
2) TOV21G-derived p53 matched pair cells: In each exper-
iment of TOV21 p53 positive and negative cell lines,
expression levels of MK-1775 treated cell lines were
divided by those of untreated cell lines with the re-ratio
algorithm in Resolver. (Calculated values were used for
clustering). In each experiment of TOV21 p53 positive
and negative cell lines, gene expression of MK-1775
treated cell lines were divided by those of only gemcitab-
ine treated cell lines with the re-ratio algorithm in
Resolver. (Calculated values were used for signature selec-
tion). After the re-ratio, signature genes, whose expression
levels in MK-1775 treated cell lines were significantly up-
or down-regulated compared to those of gemcitabine
treated cell lines (p ≤ 0.01), were selected in all compari-
sons. Among the signatures, we further selected genes
which exhibited greater than three-fold expression change
in at least one condition in both vector and control sam-
ples.
For each set of the selected signatures, hierarchical cluster-
ing was done by the Rosetta Resolver system with cosine
correlation and average link options.
Quantitative RT-PCR Analysis
cDNA was synthesized from 1 μg of total RNA by using
TaqMan reverse transcription reagents (PE Applied Bio-
systems, #N8080234). Quantitative real-time PCR assays
for human CLSPN, CCNE1/2, MCM10, FBXO5, and
GAPDH were performed in triplicate for cDNA samples in
96-well optical plates. Data were collected and analyzed
using an ABI PRISM 7700 sequence detector system (PE
Applied Biosystems). Primer and probe sequences for the
quantitative RT-PCR are as follows: primers for CLSPN, 5'-
AGGTGGAGGAAGGAGCGAA-3', 5'-TTTCCCCTGCTGT-
GCCAT-3'; Taqman probe for CLSPN, 5'-TGAACGAGAG-
CAGTGGCTTCGGG-3'; primers for CCNE1, 5'-
AAATGGCCAAAATCGACAGG-3', 5'-TGCATTATTGTC-
CCAAGGCTG-3'; Taqman probe for CCNE1: 5'-
CGGCGAGGGACCAGTGTGGG-3'; primers for CCNE2
by SYBR Green method, 5'-CTATTTGGCTATGCTGGAG-
GAAGT 3', 5'-TTCAGTGCTCTTCGGTGGTGT-3'; primers
for MCM10 by SYBR Green method, 5'-CTCCAGATC-
CCAAAAGCTCATC-3', 5'-TGTTCCGAGAAATCGTCTG-
TAGG-3'; primers for FBXO5 by SYBR Green method, 5'-
TGAAGAAGGTAGCCTCCTGGAG-3', 5'-TGGCAG-
CAAGTTTTTGTTGG-3'.
Phosphorylated-CDC2 assay
Tumors were isolated 8 hr after MK-1775 dosing. CDC2
protein was solubilized by homogenizing cells in buffer
containing 1% NP40, 0.1% Triton X-100, and was
detected by Western blotting with an anti-p-CDC2Y15
specific antibody (Cell Signaling #9111). The captured
antibodies were detected and stained with biotinylated
anti-IgG and streptavidin/horse radish peroxidase. The
immunostained area was quantified using Image Pro Plus
software (Media Cybertics Inc.).
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